88095-61-8

Usage

Uses

Used in Pharmaceutical Industry:
1-Benzyl-4-nitro-1H-pyrazole is utilized as a pharmaceutical agent for its diverse biological activities, including its anti-inflammatory, antiviral, and antitumor properties. Its potential to modulate various biological pathways and target specific diseases makes it a promising candidate for the development of new therapeutics.
Used in Agrochemical Industry:
In the agrochemical sector, 1-Benzyl-4-nitro-1H-pyrazole is employed as an insecticidal agent, leveraging its insecticidal properties to control and manage pest populations in agricultural settings.
Used as a Ligand for Metal Complexation:
1-Benzyl-4-nitro-1H-pyrazole is used as a ligand in the formation of metal complexes, which can exhibit unique chemical and physical properties. This application is valuable in various fields, including catalysis, materials science, and medicinal chemistry.
Used as a Precursor in Synthesis:
1-Benzyl-4-nitro-1H-pyrazole also serves as a precursor in the synthesis of other biologically active compounds, contributing to the development of novel pharmaceuticals and agrochemicals with improved efficacy and selectivity.
Overall, the multifaceted applications of 1-Benzyl-4-nitro-1H-pyrazole underscore its significance as a versatile chemical entity with broad implications in both medicinal and agricultural chemistry.

InChI:InChI=1/C10H9N3O2/c14-13(15)10-6-11-12(8-10)7-9-4-2-1-3-5-9/h1-6,8H,7H2

Upstream product

• 2075-46-9 4-nitro-1H-pyrazole 
• 620-05-3 iodomethylbenzene 
• 50877-42-4 1-benzyl-4-iodo-1H-pyrazole 
• 100-39-0 benzyl bromide 

Downstream Products

• 90920-49-3 1-(p-nitrobenzyl)-4-nitropyrazole 
• 1557233-35-8 N-(1-benzyl-1H-pyrazol-4-yl)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f ]indazole-3-carboxamide 
• 1557232-37-7 N-(1-benzyl-1H-pyrazol-4-yl)-1,4,5,7-tetrahydrospiro[indazole-6,3'-oxetane]-3-carboxamide 
• 1557232-34-4 N-(1-benzyl-1H-pyrazol-4-yl)-1',4',5',7'-tetrahydrospiro[cyclopropane-1,6'-indazole]-3'-carboxamide 
• 1557232-63-9 N-(1-benzyl-1H-pyrazol-4-yl)-6,6-difluoro-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide 
• 1557232-13-9 N-(1-benzyl-1H-pyrazol-4-yl)-5,5-dimethyl-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide 
• 1557232-08-2 N-(1-benzyl-1H-pyrazol-4-yl)-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide 
• 1557235-76-3 (6R)-N-(1-benzyl-1H-pyrazol-4-yl)-1',4,4',5,5',7'-hexahydro-2H-spiro[furan-3,6'-indazole]-3'-carboxamide 
• 1557235-77-4 (6S)-N-(1-benzyl-1H-pyrazol-4-yl)-1',4,4',5,5',7'-hexahydro-2H-spiro[furan-3,6'-indazole]-3'-carboxamide 

Relevant academic research and scientific papers

Design and synthesis of anti-tumor compounds containing ferulic acid-pyrazole skeleton

The invention discloses design and a preparation method of an anti-tumor compound containing a ferulic acid-pyrazole skeleton. The structure of the anti-tumor compound is shown as a formula in the specification.

COMPOUNDS AND USES THEREOF

The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

Design, synthesis, and biological evaluation of pyrazole derivatives containing acetamide bond as potential BRAFV600E inhibitors

With the increasingly acquired resistance, relapse and side effects of known marketed BRAFV600E inhibitors, it's significant to design the more effective and novel drugs. In this study, a series of novel pyrazole derivatives containing acetamid

Identification and Biological Evaluation of Novel Type II B-RafV600E Inhibitors

The mitogen-activated protein kinase (MAPK) pathway plays a vital role in signal transduction networks. Severe diseases may be triggered if it is disturbed by mutated components, especially the kinase B-RafV600E. New inhibitors of the kinase ar

C-H arylation of nitroimidazoles and nitropyrazoles guided by the electronic effect of the nitro group

A palladium-catalyzed C-H arylation reaction of nitroimidazoles and nitropyrazoles was developed using aryl bromides as arene donors. The electron-withdrawing effect of the nitro group allows for direct C-H arylation reactions of the nitro diazoles with h

Property- and structure-guided discovery of a tetrahydroindazole series of interleukin-2 inducible t-cell kinase inhibitors

Interleukin-2 inducible T-cell kinase (ITK), a member of the Tec family of tyrosine kinases, plays a major role in T-cell signaling downstream of the T-cell receptor (TCR), and considerable efforts have been directed toward discovery of ITK-selective inhibitors as potential treatments of inflammatory disorders such as asthma. Using a previously disclosed indazole series of inhibitors as a starting point, and using X-ray crystallography and solubility forecast index (SFI) as guides, we evolved a series of tetrahydroindazole inhibitors with improved potency, selectivity, and pharmaceutical properties. Highlights include identification of a selectivity pocket above the ligand plane, and identification of appropriate lipophilic substituents to occupy this space. This effort culminated in identification of a potent and selective ITK inhibitor (GNE-9822) with good ADME properties in preclinical species.

Faujasite catalyzed nitrodeiodination of iodopyrazoles

Nitrodeiodination of iodopyrazoles using nitric acid/Faujasite has been investigated. The present procedure is simple, rapid and convenient and requires no sulfuric acid or oleum and may be applied for the synthesis of several nitropyrazoles in good yield

Silica-sulfuric acid catalyzed nitrodeiodination of iodopyrazoles

We report here the synthesis of nitropyrazoles in good to excellent yields from iodopyrazoles over silica-sulfuric acid catalyst for the first time. The present procedure require less acid, offers a simplified workup procedure, and may be applied for the

HETEROCYCLIC GAMMA SECRETASE MODULATORS

The invention relates to methods for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome which comprise ad